Business Context and Reporting Period
This Form 8-K Current Report was filed by Reneo Pharmaceuticals, Inc. (not Onkure Therapeutics, Inc.) on June 2, 2022, regarding events occurring on June 1, 2022. The registrant is a Delaware corporation with its principal executive offices in Irvine, California, and its common stock trades on The Nasdaq Stock Market under the symbol RPHM. The company is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and does not contain financial performance data.
Material Changes and Voting Results
The report details the results of the 2022 Annual Meeting of Stockholders held on June 1, 2022. As of the record date (April 4, 2022), 24,458,550 shares were outstanding and entitled to vote.
Proposal 1: Election of Directors
Stockholders elected two Class I directors to serve until the 2025 Annual Meeting:
- Eric M. Dube, Ph.D.: 18,100,489 votes For; 795,195 Abstain; 2,790,889 Broker Non-Votes.
- Paul W. Hoelscher: 18,877,021 votes For; 18,663 Abstain; 2,790,889 Broker Non-Votes.
Proposal 2: Ratification of Independent Auditor
Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
- For: 21,675,242
- Against: 11,300
- Abstain: 31
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of voting results.
Investor Verification Checklist
- Verify the correct registrant name is Reneo Pharmaceuticals, Inc. (RPHM), not Onkure Therapeutics, Inc.
- Confirm the successful election of Eric M. Dube and Paul W. Hoelscher to the Board of Directors.
- Note the high level of support for the ratification of Ernst & Young LLP (over 21.6 million votes For vs. 11,300 Against).
- Review the company's most recent 10-K or 10-Q filings for financial metrics, as this 8-K contains no financial data.